Papillary Thyroid CarcinomaNCT07695974
Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma
An observational study of Papillary Thyroid Carcinoma and Recurrence Free Survival, run by University of Roma La Sapienza at 1 site in Italy.
Trial summary
The goal of this observational study is to identify demographic and clinicopathological factors associated with disease recurrence in adults with histologically confirmed papillary thyroid carcinoma (PTC) who achieved an initial disease-free status after primary treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Papillary Thyroid Carcinoma, Recurrence Free Survival
- How many people
- 1,113 participants
- Where
- 1 siteItaly
- Study dates
- 7 Jan 2000to 15 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consisted of adult patients treated for histologically confirmed papillary thyroid carcinoma at the Department of Surgery of Sapienza University of Rome, Policlinico Umberto I Hospital, between 2000 and 2018. Patients were identified from a prospectively maintained institutional database and had undergone primary surgical treatment and subsequent postoperative surveillance at the same tertiary referral center.
Who may be able to join
- histologically confirmed diagnosis of papillary thyroid carcinoma
- no history of previous neck surgery
- availability of complete clinical, pathological, treatment, and follow-up data;
- achievement of an initial disease-free status after primary treatment
- minimum follow-up of 60 months for patients who remained recurrence-free
Who cannot join
- histological diagnosis other than papillary thyroid carcinoma
- previous neck surgery
- incomplete clinical, pathological, treatment, or follow-up records
- follow-up shorter than 60 months in patients without recurrence
- biochemical or structural evidence of persistent disease after initial treatment
Trial locations and contacts
1 site in 1 country.
Italy1 site
Sapienza University of Rome - Policlinico Umberto I Hospital
Roma, 00161
About this study
Official title: Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma: Evidence From a Large Cohort of Patients With Extended Follow-up
The goal of this observational study is to identify demographic and clinicopathological factors associated with disease recurrence in adults with histologically confirmed papillary thyroid carcinoma (PTC) who achieved an initial disease-free status after primary treatment.
The main questions it aims to answer are:
Read more
Which demographic and clinicopathological characteristics are associated with an increased risk of PTC recurrence?
Researchers will compare patients who developed biochemical or structural recurrence with those who remained recurrence-free to assess the prognostic role of age, sex, tumor size, histological subtype, vascular invasion, capsular invasion, gross invasion of the prethyroid strap muscles, concomitant thyroiditis, multifocality, lymph-node status, and pathological stage.
As this is a retrospective study, participants will not undergo any study-specific intervention or additional procedure. Researchers will review existing demographic, surgical, pathological, treatment, and follow-up data from a prospectively maintained institutional database. Follow-up data include serial serum thyroglobulin measurements, neck ultrasonography, recurrence, and disease-specific mortality.
Read the detailed description
A retrospective cohort study was conducted with the aim of evaluating the risk of recurrence in relation to age (cut-off: 55 years), sex, tumor diameter, histological subtype (aggressive vs non-aggressive), vascular invasion, capsular invasion, muscular invasion, the presence of thyroiditis, multifocality and overall stage.
For each patient, demographic and clinicopathological data were collected, including age, sex, type of surgery (total thyroidectomy ± central/lateral neck dissection), histological subtype of PTC, presence of thyroiditis (as defined by histological examination), vascular invasion, capsular invasion (histological involvement of the thyroid capsule), muscular invasion (defined as gross extrathyroidal extension limited to the prethyroid strap muscles), tumor multifocality (presence of two or more distinct PTC foci, whether ipsilateral or contralateral to the dominant tumor) , lymph-node status, TNM classification, and final pathological stage (assigned according to the 8th edition of the AJCC TNM classification system). Recurrence and disease-specific mortality were also evaluated. Recurrence was defined as any biochemical or structural evidence of disease arising after the achievement of an initial disease-free status. For patients who developed recurrence, follow-up ended at the time of recurrence, which was considered the event endpoint.
Surgical management included hemithyroidectomy in patients with indeterminate cytology, and total thyroidectomy in cases with multinodular goiter or cytological findings suspicious for or diagnostic of malignancy, according to the cytological classification and clinical guidelines in force at the time of treatment. Patients with TIR 4 or TIR 5 cytology underwent concomitant central compartment lymph node dissection (CLND), whereas patients with TIR 3b cytology or multinodular goiter did not. Lateral neck dissection was performed in all patients with radiological evidence of lymph node metastases. Postoperative management and follow-up were conducted in accordance with the international and national guidelines in force during the study period. Routine follow-up included serial serum thyroglobulin measurements and neck ultrasonography. Postoperative treatment included radioiodine therapy in patients with aggressive histological subtypes and/or advanced stage disease. All patients received suppressive therapy with levothyroxine sodium for a minimum of 5 years.
All histopathological examinations were performed by a dedicated endocrine pathologist with more than 10 years of experience. Histological subtypes of PTC were categorized as aggressive (solid, columnar cell, diffuse sclerosing, hobnail and tall cell subtypes - PTC-sol, PTC-col, PTC-sc, PTC-h and PTC-t.c, respectively) or non-aggressive (classic, follicular, oncocytic, Warthin-like, and ossifying subtypes - PTC-c, PTC-f, PTC-onco, PTC-W, and PTC-oss, respectively), according to established morphological criteria. Tumor size, based on histological examination, was stratified into three categories: ≤1 cm, >1-2.5 cm, and >2.5 cm.
Statistical analysis Categorical variables were expressed as absolute and relative frequencies. The association between clinicopathological variables and recurrence was initially evaluated using Pearson's chi-squared test or Fisher's exact test, as appropriate. Tumor diameter was analyzed as a categorical variable with three levels (≤1 cm, >1-2.5 cm, and >2.5 cm). The significance threshold was set at p < 0.05. To identify independent predictors of recurrence, a multivariable logistic regression model was constructed including age group (<55 vs ≥55 years), sex, tumor diameter, histological subtype (aggressive vs non-aggressive), vascular invasion, capsular and/or muscular invasion, thyroiditis, multifocality, and AJCC stage. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
To assess the association between concomitant thyroiditis and the histopathological features of papillary thyroid carcinoma (PTC), patients with histologically confirmed thyroiditis were compared with those without thyroiditis. The following pathological variables were evaluated: multifocality, capsular invasion, muscular invasion, vascular invasion, lymphatic invasion, tumor size (<2.5 cm vs ≥2.5 cm), and disease stage (I-II vs III-IV).Categorical variables were reported as counts and percentages and compared using Pearson's χ² test or Fisher's exact test, as appropriate. Associations between thyroiditis and tumor characteristics were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). To account for multiple comparisons, p values were adjusted using the Holm sequential procedure. Holm-adjusted p values <0.05 were considered statistically significant.
Survival analysis was performed using the Kaplan-Meier method, and differences in disease-free survival between groups were assessed with the log-rank test. Cox proportional hazards regression analysis was used to estimate hazard ratios (HRs) and their 95% CIs for recurrence. Variables included in the multivariable Cox models were selected a priori based on clinical relevance and univariable results. A secondary Cox regression analysis was restricted to events occurring within the first five years of follow-up. No significant differences were observed between the results of the 5-year and 10-year analyses.
- Keywords
- Papillary thyroid carcinoma, Disease recurrence, Prognostic factors, Risk stratification, 5-year follow-up
- Medical subject headings
- Thyroid Cancer, Papillary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Disease-free | The disease-free group included patients who achieved an initial disease-free status after primary treatment and showed no biochemical or structural evidence of recurrence during follow-up. | |
| With recurrence | The recurrence group included patients who achieved an initial disease-free status after primary treatment and subsequently developed documented biochemical or structural recurrence. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrence
biochemical or structural evidence of disease arising after the achievement of an initial disease-free status.
Measured: From surgery to the end of follow-up (minimum of 60 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start7 Jan 2000
- Primary completion31 Aug 2018
- Study completion15 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Papillary Thyroid CarcinomaStudies of the same condition, open and under way.
- More trials run by University of Roma La SapienzaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,113 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Roma La Sapienza
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eleonora Lori, MD, University of Roma La Sapienza
- Investigators
- Eleonora Lori, MD, Principal investigator, University of Roma La SapienzaSalvatore Sorrenti, MD, PhD, Study chair, University of Roma La Sapienza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07695974
- Sponsor's protocol ID
- 2615
- Status last verified
- Jul 2026
- First submitted
- 5 Jul 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma: Evidence From a Large Cohort of Patients With Extended Follow-up
- ClinicalTrials.gov ID
- NCT07695974
- Acronym / sponsor ID
- 2615
- Keywords
- Papillary thyroid carcinoma, Disease recurrence, Prognostic factors, Risk stratification, 5-year follow-up
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,113 participants (actual)
- Lead sponsor
- University of Roma La SapienzaUniversity, hospital or other
- Study start
- 7 Jan 2000 (actual)
- Primary completion
- 31 Aug 2018 (actual)
- Study completion
- 15 Jan 2024 (actual)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to identify demographic and clinicopathological factors associated with disease recurrence in adults with histologically confirmed papillary thyroid carcinoma (PTC) who achieved an initial disease-free status after primary treatment.
The main questions it aims to answer are:
Which demographic and clinicopathological characteristics are associated with an increased risk of PTC recurrence?
Researchers will compare patients who developed biochemical or structural recurrence with those who remained recurrence-free to assess the prognostic role of age, sex, tumor size, histological subtype, vascular invasion, capsular invasion, gross invasion of the prethyroid strap muscles, concomitant thyroiditis, multifocality, lymph-node status, and pathological stage.
As this is a retrospective study, participants will not undergo any study-specific intervention or additional procedure. Researchers will review existing demographic, surgical, pathological, treatment, and follow-up data from a prospectively maintained institutional database. Follow-up data include serial serum thyroglobulin measurements, neck ultrasonography, recurrence, and disease-specific mortality.
Detailed description
A retrospective cohort study was conducted with the aim of evaluating the risk of recurrence in relation to age (cut-off: 55 years), sex, tumor diameter, histological subtype (aggressive vs non-aggressive), vascular invasion, capsular invasion, muscular invasion, the presence of thyroiditis, multifocality and overall stage.
For each patient, demographic and clinicopathological data were collected, including age, sex, type of surgery (total thyroidectomy ± central/lateral neck dissection), histological subtype of PTC, presence of thyroiditis (as defined by histological examination), vascular invasion, capsular invasion (histological involvement of the thyroid capsule), muscular invasion (defined as gross extrathyroidal extension limited to the prethyroid strap muscles), tumor multifocality (presence of two or more distinct PTC foci, whether ipsilateral or contralateral to the dominant tumor) , lymph-node status, TNM classification, and final pathological stage (assigned according to the 8th edition of the AJCC TNM classification system). Recurrence and disease-specific mortality were also evaluated. Recurrence was defined as any biochemical or structural evidence of disease arising after the achievement of an initial disease-free status. For patients who developed recurrence, follow-up ended at the time of recurrence, which was considered the event endpoint.
Surgical management included hemithyroidectomy in patients with indeterminate cytology, and total thyroidectomy in cases with multinodular goiter or cytological findings suspicious for or diagnostic of malignancy, according to the cytological classification and clinical guidelines in force at the time of treatment. Patients with TIR 4 or TIR 5 cytology underwent concomitant central compartment lymph node dissection (CLND), whereas patients with TIR 3b cytology or multinodular goiter did not. Lateral neck dissection was performed in all patients with radiological evidence of lymph node metastases. Postoperative management and follow-up were conducted in accordance with the international and national guidelines in force during the study period. Routine follow-up included serial serum thyroglobulin measurements and neck ultrasonography. Postoperative treatment included radioiodine therapy in patients with aggressive histological subtypes and/or advanced stage disease. All patients received suppressive therapy with levothyroxine sodium for a minimum of 5 years.
All histopathological examinations were performed by a dedicated endocrine pathologist with more than 10 years of experience. Histological subtypes of PTC were categorized as aggressive (solid, columnar cell, diffuse sclerosing, hobnail and tall cell subtypes - PTC-sol, PTC-col, PTC-sc, PTC-h and PTC-t.c, respectively) or non-aggressive (classic, follicular, oncocytic, Warthin-like, and ossifying subtypes - PTC-c, PTC-f, PTC-onco, PTC-W, and PTC-oss, respectively), according to established morphological criteria. Tumor size, based on histological examination, was stratified into three categories: ≤1 cm, >1-2.5 cm, and >2.5 cm.
Statistical analysis Categorical variables were expressed as absolute and relative frequencies. The association between clinicopathological variables and recurrence was initially evaluated using Pearson's chi-squared test or Fisher's exact test, as appropriate. Tumor diameter was analyzed as a categorical variable with three levels (≤1 cm, >1-2.5 cm, and >2.5 cm). The significance threshold was set at p < 0.05. To identify independent predictors of recurrence, a multivariable logistic regression model was constructed including age group (<55 vs ≥55 years), sex, tumor diameter, histological subtype (aggressive vs non-aggressive), vascular invasion, capsular and/or muscular invasion, thyroiditis, multifocality, and AJCC stage. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
To assess the association between concomitant thyroiditis and the histopathological features of papillary thyroid carcinoma (PTC), patients with histologically confirmed thyroiditis were compared with those without thyroiditis. The following pathological variables were evaluated: multifocality, capsular invasion, muscular invasion, vascular invasion, lymphatic invasion, tumor size (<2.5 cm vs ≥2.5 cm), and disease stage (I-II vs III-IV).Categorical variables were reported as counts and percentages and compared using Pearson's χ² test or Fisher's exact test, as appropriate. Associations between thyroiditis and tumor characteristics were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). To account for multiple comparisons, p values were adjusted using the Holm sequential procedure. Holm-adjusted p values <0.05 were considered statistically significant.
Survival analysis was performed using the Kaplan-Meier method, and differences in disease-free survival between groups were assessed with the log-rank test. Cox proportional hazards regression analysis was used to estimate hazard ratios (HRs) and their 95% CIs for recurrence. Variables included in the multivariable Cox models were selected a priori based on clinical relevance and univariable results. A secondary Cox regression analysis was restricted to events occurring within the first five years of follow-up. No significant differences were observed between the results of the 5-year and 10-year analyses.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Disease-free | – | –The disease-free group included patients who achieved an initial disease-free status after primary treatment and showed no biochemical or structural evidence of recurrence during follow-up. |
| With recurrence | – | –The recurrence group included patients who achieved an initial disease-free status after primary treatment and subsequently developed documented biochemical or structural recurrence. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consisted of adult patients treated for histologically confirmed papillary thyroid carcinoma at the Department of Surgery of Sapienza University of Rome, Policlinico Umberto I Hospital, between 2000 and 2018. Patients were identified from a prospectively maintained institutional database and had undergone primary surgical treatment and subsequent postoperative surveillance at the same tertiary referral center.
Key inclusion criteria (5 listed)
- histologically confirmed diagnosis of papillary thyroid carcinoma
- no history of previous neck surgery
- availability of complete clinical, pathological, treatment, and follow-up data;
- achievement of an initial disease-free status after primary treatment
- minimum follow-up of 60 months for patients who remained recurrence-free
Key exclusion criteria (5 listed)
- histological diagnosis other than papillary thyroid carcinoma
- previous neck surgery
- incomplete clinical, pathological, treatment, or follow-up records
- follow-up shorter than 60 months in patients without recurrence
- biochemical or structural evidence of persistent disease after initial treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Recurrence
Time frame: From surgery to the end of follow-up (minimum of 60 months)
biochemical or structural evidence of disease arising after the achievement of an initial disease-free status.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Papillary Thyroid Carcinoma
Recruiting
Active Surveillance of Papillary Thyroid Microcarcinoma
Papillary Thyroid Microcarcinoma
RecruitingObservational study
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY
Papillary Thyroid Cancer
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
RecruitingObservational study
Studies on Tumors of the Thyroid
Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer
Active, not recruitingPhase 3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Differentiated Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eleonora Lori, MD principal investigator
University of Roma La Sapienza
Salvatore Sorrenti, MD, PhD study chair
University of Roma La Sapienza
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Papillary Thyroid Carcinoma and Recurrence Free Survival, run by University of Roma La Sapienza at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrence (time frame: From surgery to the end of follow-up (minimum of 60 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.